US OptionsDetailed Quotes
VRTX250502P440000
- 2.42
- 0.000.00%
15min DelayClose May 2 16:00 ET
0.00High0.00Low
2.42Open2.42Pre Close0 Volume17 Open Interest440.00Strike Price0.00Turnover4945.87%IV12.68%PremiumMay 2, 2025Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry2.42Extrinsic Value100Contract SizeAmericanOptions Type-0.0950Delta0.0032Gamma207.09Leverage Ratio-2689.8475Theta0.0000Rho-19.67Eff Leverage0.0018Vega
Vertex Pharmaceuticals Stock Discussion
Revolutionary CF Treatment Pioneer at Vertex Receives Top Medical Honor: How It Transforms Patient Care
Major EU Victory: KAFTRIO Now Approved for 4,000 More CF Patients, Including Children
Revolutionary Gene Therapy CASGEVY Now Available Through NHS England: Major Win for Sickle Cell Patients
FDA Approves First Non-Opioid Pain Drug in 20 Years: Vertex's Game-Changing Alternative to Opioids
has options
“Suzetrigine: The FDA has assigned a PDUFA target action date of January 30, 2025, for suzetrigine for the treatment of moderate-to-severe acute pain. Suzetrigine was granted Priority Review by the FDA.
The Non-Opioids Prevent Addiction In the Nation (NOPAIN) Act became effective on January 1st, 2025. The NOPAIN Act mandates that Medicare provide a separate add-on payment in the hospital outp...
nfa
SiteOne’s efforts in non-opioid pain management put it in a unique position relative to Vertex Pharmaceuticals, a major player in the field known for its successful development of cystic fibrosis treatments. Vertex has also been working on non-opioid pain drugs, specifically targeting the NaV1.8 sodium channel, a focal point shared by SiteOne’s lead pro...
At 4:02 p.m. ET, the three indices closed lower. The $Dow Jones Industrial Average (.DJI.US)$ was off 0.70%, losing 300 points. The $S&P 500 Index (.SPX.US)$ was down 1.32% and the $Nasdaq Composite Index (.IXIC.US)$ was off 2.24%.
MACRO
In macro, core retail sales grew by 0.1% month over month, lower than estimated. ...
No comment yet